Analgesic Treatment for Cancer Pain in South East Asia

NCT ID: NCT02664987

Last Updated: 2016-10-31

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 462 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2015-12-31

Brief Summary

This study is planned to investigate the pain control status in cancer patients in 6 South East Asian countries through evaluation of prescription pattern of analgesics, satisfaction of pain control, quality of life and assessment of the adequacy of pain control and relationship among these factors in cancer patients with pain. Cancer pain is undermanaged and it is hoped that this study will be used as a reference for effective cancer pain management in these countries.

Conditions

Pain

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Patients receiving cancer pain treatment

Patients receiving cancer pain treatment

Intervention Type: OTHER

Interventions

Patients receiving cancer pain treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Adult (over 18 years) cancer patients [country variation would be accepted based on the definition of adults]

2. Cancer has been diagnosed pathologically

3. Out-patients with cancer pain due to cancer itself or its treatment

4. Patients being treated with any analgesics for more than one month for the management of cancer pain at enrolment

5. Patients who are willing to voluntarily sign the study consent form

Exclusion Criteria

1. Patients who have had an operation for any reasons within 3 months prior to the enrolment

2. Patients with any oncologic emergency

3. Patients who had any interventional therapy (e.g. nerve block, neurolytic procedures) related to their cancer pain within 6 weeks of study entry

4. Insufficient ability or willingness to cooperate

5. Patients who are judged not suitable to participate in this study by the investigator

6. Patients who are participating in any other interventional clinical trials for cancer treatment or supportive care

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mundipharma Pte Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Thinh DHQ, Sriraj W, Mansor M, Tan KH, Irawan C, Kurnianda J, Nguyen YP, Ong-Cornel A, Hadjiat Y, Moon H, Javier FO. Analgesic Prescription Patterns and Pain Outcomes in Southeast Asia: Findings From the Analgesic Treatment of Cancer Pain in Southeast Asia Study. J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00055.

Reference Type: DERIVED

PMID: 30241271 (View on PubMed)

Thinh DHQ, Sriraj W, Mansor M, Tan KH, Irawan C, Kurnianda J, Nguyen YP, Ong-Cornel A, Hadjiat Y, Moon H, Javier FO. Patient and Physician Satisfaction with Analgesic Treatment: Findings from the Analgesic Treatment for Cancer Pain in Southeast Asia (ACE) Study. Pain Res Manag. 2018 Apr 18;2018:2193710. doi: 10.1155/2018/2193710. eCollection 2018.

Reference Type: DERIVED

PMID: 29849841 (View on PubMed)

Other Identifiers

OPD14-AP-401

Identifier Type: -

Identifier Source: org_study_id